Tumor treating fields (TTFields) inhibit cancer cell migration and invasion by inducing reorganizing of the actin cytoskeleton and formation of cell adhesions.

Poster Presentation

Time: 7:30 – 9:30 p.m. PT

CBIO-30
Tumor treating fields (TTFields) inhibit cancer cell migration and invasion by inducing reorganizing of the actin cytoskeleton and formation of cell adhesions
Schneiderman, R
Cell Biology

CSG-01
Tumor Treatment Fields downregulate specific transcription factors leading to reduced DNA repair capacity, increased replication stress, the inhibition of mitophagy and enhanced cell death
Story, M
Cell Signaling and Signaling Pathways

EXTH-04
Guiding principles for predicting the distribution of tumor treating fields in a human brain: A computer modeling study investigating the impact of tumor position, conductivity distribution and tissue homogeneity
Korshoj, AR
Experimental Therapeutics - Non-immunological

EXTH-19
Combination of in vitro Tumor Treating Fields and temozolomide decrease proliferation in patient-derived glioblastoma cell lines
Michelhaugh, S
Experimental Therapeutics - Non-immunological

EXTH-22
A new design for transducer arrays for the delivery of Tumor Treating Fields
Bomzon, Z
Experimental Therapeutics - Non-immunological

EXTH-33
To achieve greater efficacy in tumor treatment fields: modeling based on the intracellular mechanisms
Carlston, K
Experimental Therapeutics - Non-immunological

EXTH-45
The combination of TTFields and ABT-414 demonstrate superior efficacy against glioma cells
Schneiderman, R
Experimental Therapeutics - Non-immunological

EXTH-66
Glioblastoma cells from a patient post-Tumor Treating Fields (TTFields) therapy are sensitive to TTFields in vitro
Michelhaugh, S
Experimental Therapeutics - Non-immunological

EXTH-76
Optimizing transducer array configuration for treating tumors in the infratentorial and supratentorial brain using Tumor Treating Fields (TTFields)
Levi, S
Experimental Therapeutics - Non-immunological

HOUT-06
TTFields for newly diagnosed Glioblastoma: Impact of consultation strategy
Proescholdt, M
Health Outcome Measures

NCGD-05
Time to functional and cognitive decline in a phase III trial of tumor treating fields with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma
Nicholas, G
Neuro-Cognitive Outcomes

NIMG-03
Quantitative MR measurements in glioblastoma patients: difference in mean diffusivity between Optune® patients and patients with only standard treatment
Vymazal, J
Neuroimaging

NIMG-18
Creating accurate computational head models of patients using dataset combining MRI and CT images
Naveh, A
Neuroimaging

NIMG-66
A method for rapidly creating head models of Glioblastoma patients for studying the delivery of TTFields to the brain
Urman, N
Neuroimaging

NIMG-67
Advanced perfusion and diffusion MR imaging in glioblastoma patients treated with Tumor Treating Fields (TTFields) as first-line therapy
Connelly, J. M
Neuroimaging

NIMG-92
Volumetric response to TTFields in newly diagnosed GBM
Freyschlag, CF
Neuroimaging

PALL-01
One year with Optune® in Austria: First report on clinical outcomes
Kerschbaumer, J
Supportive Palliative Care

POCT-07
Tumor treating fields for pediatric patients with high grade glioma: first case series in Germany
Wolf, M
Pediatric Clinical Trials and Outcomes

QFIF-10
Long term Survival in Glioblastoma Patients After Tumor Treating Fields (TTFields) Therapy
Ruska, A
Quality of Life

QFIF-16
Clinical and Social Challenges & Opportunities in Treating Glioblastoma with Tumor Treating Fields: A Case Series
Nguyen, M
Quality of Life

QFIF-20
Skin care products compatible with Tumor Treating Fields
Lacouture, M
Quality of Life

QFIF-25
Effect of Tumor Treating Fields (TTFields) on health-related quality of life (HRQoL) in newly diagnosed glioblastoma. Results of the EF-14 randomized phase III trial
Taghero, M.J.B
Quality of Life

QFIF-32
Meeting the needs: Platforms for patients using Optune® to exchange expertise
Kebler, A. F
Quality of Life

QFIF-36
Role of nurses for the implementation of TTFields in daily clinical routine in glioblastoma treatment
Killas, M
Quality of Life

QFIF-38
Tumor treating fields for the treatment of glioblastoma Multiforme in daily praxis: experience from two hospitals in Germany
May, S
Quality of Life

QFIF-42
Incidence and characterization of dermatologic adverse events in patients treated with Tumor Treating Fields and impact on overall survival
Sumral, A
Quality of Life
SATURDAY, NOVEMBER 18

ORAL PRESENTATION

10:30 – 11:00 a.m. PT.
ACTR-102 Patterns of TTFields-related severe skin toxicity in GBM patients
Kerber, M
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-103 The effect of TTFields treatment on survival in glioblastoma patients and the relationship to glioma grade: a post hoc analysis of the OPTIMAL TTFields study
Kew, Y
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-104 A phase II study of Tumor Treating Fields and Bevacizumab in recurrent or progressive Meningioma
Kamath, S
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-105 A Phase II Study of TTFields and Pulsed Bevacizumab in Patients with Bevacizumab-Induced Pneumonitis
Boulos, J
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-106 Synergistic Inhibition of Glioma Cell Proliferation by Withaferin A and Tumor Treating Fields
Kwon, Y
Immunologic

10:30 – 11:00 a.m. PT.
ACTR-107 Study of pembrolizumab, tumor treatment fields (Optune®) and temozolomide for patients with recurrent glioblastoma: a post hoc analysis of the OPTIMAL TTFields study
Kesari, S
Adult Clinical Trials - Immunologic

10:30 – 11:00 a.m. PT.
ACTR-108 End-to-end workflow for finite element analysis of TTFields in Glioblastoma
Menshikov, Y
Immunologic

10:30 – 11:00 a.m. PT.
ACTR-109 Finding a predictive marker for compliance to TTFields therapy – preliminary results and trial design
Korshoej, AR
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-110 Patterns of TTFields-related severe skin toxicity in GBM patients
Kerber, M
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-111 Feasibility of a concomitant administration of alternating electric fields and Bevacizumab therapy for glioblastoma patients
Voloshin, T
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-112 Radiation therapy targeting accuracy when combined with alternating electric field therapy
Grimm, J
Radiation Therapy

10:30 – 11:00 a.m. PT.
ACTR-113 The estimated long-term survival benefit of adding TTFields to the standard of care for glioblastoma patients
Proescholdt, M. A
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-114 Evaluation of the in-vitro effects of Tumor Treating Fields on T-cell responses
Feeney, M
Immunologic

10:30 – 11:00 a.m. PT.
ACTR-115 A Phase II study of tumor treating fields (TTFields) with temozolomide in patients with newly diagnosed glioblastoma
Fieseler, M A
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-116 Radiosurgery and tumor treating fields in small cell lung cancer patients: a pilot and feasibility trial
Dulany, C
Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-117 Alternating electric fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy
Kesari, S
Adult Clinical Trials - Immunologic

10:30 – 11:00 a.m. PT.
ACTR-118 Adult Clinical Trials - Non-Immunologic

10:30 – 11:00 a.m. PT.
ACTR-119 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-120 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-121 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-122 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-123 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-124 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-125 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-126 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-127 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-128 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-129 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-130 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-131 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-132 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-133 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-134 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-135 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-136 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-137 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-138 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-139 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-140 Immunologic

10:30 – 11:00 a.m. PT.
ACTR-141 Immunologic